Comparative Study of CTD Modules 3, 4, and 5: Generic Drugs versus Complex Generics (Liposomal Injectables) in the United States, European Union, and Japan
Abstract
Liposomal drug delivery systems form an important branch of pharmaceutical product nanomedicine. Unlike traditional small-molecule generics, structural and physicochemical characteristics of a lipid carrier system do not only regulate the therapeutic behavior of an active pharmaceutical ingredient but also influence it. The liposomal formulations are therefore categorised as complex generics or non-biological complex drugs (NBCDs). To prove the similarity of liposomal generics and their reference products would thus require a wider range of analytical, non-clinical and clinical data in comparison with traditional generics. The current paper compares liposomal complex generics regulatory expectations in 3 major jurisdictions of the United States, the European Union, and Japan. The comparison will be made on the Common Technical Document(CTD) Modules 3, 4, and 5, which indicate, quality documentation, non-clinical evidence, and clinical evidence respectively. Regulations and peer-reviewed literature have been analyzed in order to determine variation in regulatory demands across these areas. The results show that complex generics require thorough description of physicochemical properties, biological activity as well as pharmacokinetic functioning due to the impact of nanoscale structural features on drug targeting and toxicity. Regulatory agencies vary in their scientific principles even though they have similar principles of regulation. European Union is focused on comparability in detail; Japan focuses more on mechanistic non-clinical evaluation and the United States uses a risk-based regulatory model which incorporates quality attributes and pharmacokinetic data. These regulatory differences can help pharmaceutical developers to understand before submitting liposomal complex generics to global regulations.
Conclusion:Liposomal generics require more extensive evaluation than traditional generics, including detailed structural and biological characterization. Regulatory expectations differ: Europe emphasizes analytical comparability, Japan focuses on nonclinical studies, and the US follows a risk-based approach with quality and PK data. Understanding these regional differences is essential for efficient development and successful global submissions.
Downloads
References
2. Klein K, Borchard G, Shah VP, Flühmann B, McNeil SE, de Vlieger JSB. A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways. Ann N Y Acad Sci [Internet]. 2021 [cited 2026 Jan 04];1502(1):5-13. Available from:
https://doi.org/10.1111/nyas.14662
3. Avhad PA, Chalikwar SS, Bhairav BA. A comprehensive review on complex generics. Bull Karaganda UnivBiol Med Geogr Ser [Internet]. 2022 Mar [cited 2026 Jan 02];105(1):129-35. Available from:
https://doi.org/10.31489/2022bmg1/129-13
4. Beltrán-Gracia E, López-Camacho A, Higuera-Ciapara I, Velázquez-Fernández JB, Vallejo-Cardona AA. Nanomedicine review: Clinical developments in liposomal applications. Cancer Nanotechnol [Internet]. 2019 [cited 2026 Jan 05];10:1-10. Available from:
https://doi.org/10.1186/s12645-019-0055-y
5. Wang Y, Grainger DW. Regulatory considerations specific to liposome drug development as complex drug products. Front Drug Deliv [Internet]. 2022 [cited 2026 Jan 04];2:901281. Available from:
https://doi.org/10.3389/fddev.2022.901281
6. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol [Internet]. 2015 [cited 2026 Jan 02];6:286. Available from:
https://doi.org/10.3389/fphar.2015.00286
7. Demina NB, Bakhrushina EO, Anurova MN, Merkushova AG, Pomytkina MV, Rastopchina OV, et al. Complex generics as a trend of modern pharmaceutical development. Int J Appl Pharm [Internet]. 2024 [cited 2026 Feb 05];16(3):71-7. Available from:
https://doi.org/10.22159/ijap.2024v16i3.49937
8. Murthy SK. Nanoparticles in modern medicine: State of the art and future challenges. Int J Nanomedicine [Internet]. 2007 [cited 2026 Feb 04];2(2):129-41.
9. Kateregga I, Naga Shubha B. Regulatory challenges in complex generics: A focus on liposomal and nanoparticulate drug products. Int J Sci Res Arch [Internet]. 2025 Mar [cited 2026 Jan 06];14(3):834-49. Available from:
https://doi.org/10.30574/ijsra.2025.14.3.0730
10. Jadhav PA, Dhumal SM. A review on liposomes as a novel drug delivery system. Int J Sci Res Sci Technol [Internet]. 2024 Oct [cited 2026 Jan 02];11(5):362-72. Available from:
https://doi.org/10.32628/ijsrst24115112
11. Rajan R, Jose S, Biju MV, Vasudevan D. Transferosomes - A vesicular transdermal delivery system for enhanced drug permeation. J Adv Pharm Technol Res [Internet]. 2011 [cited 2026 Jan 02];2(3):138-43. Available from:
https://doi.org/10.4103/2231-4040.85524
12. Choudhury A. Liposome: a carrier for effective drug delivery. J Appl Pharm Res [Internet]. 2020 Mar [cited 2026 Jan 06];8(1):22-8. Available from:
https://doi.org/10.18231/j.joapr.2019.v.8.i.1.003
13. Sreedevi A, Musmade PB, Bhat K, Dharmagadda S, Janodia MD, Bhat BB, et al. A deep dive into the development of complex generics: A comprehensive review. J Appl Pharm Sci [Internet]. 2024 [cited 2026 Jan 05];14(4):1-14. Available from:
https://doi.org/10.7324/JAPS.2024.204337
14. Farooque F, Wasi M, Mughees MM. Liposomes as drug delivery system: An updated review. J Drug DelivTher [Internet]. 2021 Oct [cited 2026 Jan 06];11(5-S):149-58. Available from:
https://doi.org/10.22270/jddt.v11i5-s.5063
15. Liu P, Chen G, Zhang J. A review of liposomes as a drug delivery system: Current status of approved products, regulatory environments, and future perspectives. Molecules [Internet]. 2022 [cited 2026 Feb 02];27(4):1372. Available from:
https://doi.org/10.38212/2224-6614.3441
16. Jiang Y, Li W, Wang Z, Lu J. Lipid-based nanotechnology: Liposome. Pharmaceutics [Internet]. 2024 [cited 2026 Jan 02];16(1):34. Available from:
https://doi.org/10.3390/pharmaceutics16010034
17. Liposome drug products: Chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation guidance for industry [Internet]. US:USFDA;2018 [cited 2026 Jan 02];1-38. Available from:
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/liposome-drug-products-chemistry-manufacturing-and-controls-human-pharmacokinetics-and
18. Drug and device manufacturer communications with payors, formulary committees, and similar entities: questions and answers guidance for industry and review staff [Internet]. 2018 [cited 2026 Jan 02];1-25.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
